Fund moves
2 tracked managers disclosed the same change for Q4 2024. From a 13F filed Feb 14, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Mar 24, 2025 · Filed Mar 25, 2025
A Monte Rosa Therapeutics director paid $58K out of pocket for Monte Rosa Therapeutics shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$58,383
Shares × reported transaction price
$25K–$100K
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
4 days after results of Mar 20, 2025, 45 days before results of May 8, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
Fund moves
2 tracked managers disclosed the same change for Q4 2024. From a 13F filed Feb 14, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Fund moves
2 tracked managers disclosed the same change for Q4 2024. From a 13F filed Feb 14, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.